Drug Information

Drug General Information
Drug ID
D0NT1S
Former ID
DNCL002584
Drug Name
CB-10-01
Drug Type
Vaccine
Indication Melanoma [ICD9: 172; ICD10:C43] Phase 2 [522705]
Company
Cosmo Pharmaceuticals
Target and Pathway
Target(s) Telomerase reverse transcriptase Target Info [528698]
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Validated targets of C-MYC transcriptional activation
Regulation of Telomerase
IL2 signaling events mediated by PI3K
Regulation of nuclear beta catenin signaling and target gene transcription
HIF-1-alpha transcription factor network
Reactome Formation of the beta-catenin:TCF transactivating complex
References
Ref 522705ClinicalTrials.gov (NCT00925314) A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma. U.S. National Institutes of Health.
Ref 528698Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.